Clinical implication of HLA class I expression in breast cancer

Kaneko, Koichi; Ishigami, Sumiya; Kijima, Yuko; Funasako, Yawara; Hirata, Munetsugu; Okumura, Hiroshi; Shinchi, Hiroyuki; Koriyama, Chihaya; Ueno, S.; Yoshinaka, Heiji; Natsugoe, Shoji

doi:10.1186/1471-2407-11-454

Cited by 109 publications

(108 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although previous reports have shown HLA class I downregulation, particularly in breast cancer, 7 - 9 our results revealed that most of the tumors exhibited high expression of HLA class I molecules and that the expression within the tumor area was higher than that outside (unpublished data).…”

Section: Hla Class I Expression Within and Outside Of A Tumorcontrasting

confidence: 58%

Peptide intra-tumor injection for cancer immunotherapy

Nobuoka

Yoshikawa

Fujiwara

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

One of the problems in antigen-specific cancer immunotherapy is the low density of the tumor antigen-derived peptide endogenously presented on tumor cell surface major histocompatibility complex class I molecules. To overcome this, we are engaged in research on peptide intra-tumor injection to enhance tumor cell antigenicity. In in vivo studies using immunodeficient mice, the peptide injected into a solid mass of subcutaneous tumor was revealed to be loaded onto human leukocyte antigen class I molecules of tumor cells. In a peptide vaccine model and an adoptive cell transfer model using C57BL/6 mice, peptide intra-tumor injection was effective in terms of tumor growth inhibition and prolongation of survival time. Moreover, an antigen-spreading effect was detected after peptide intra-tumor injection. Peptide intra-tumor injection is an effective method of enhancing tumor cell antigenicity. It can induce additional peptide loading onto tumor cells, making tumor cells more antigenic for specific cytotoxic T-lymphocyte activity. Peptide intra-tumor injection may be a useful option for improvement of antigen-specific immunotherapy against solid tumors.

show abstract

Section: Hla Class I Expression Within and Outside Of A Tumorcontrasting

confidence: 58%

Peptide intra-tumor injection for cancer immunotherapy

Nobuoka

Yoshikawa

Fujiwara

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The down regulation of HLA class I expression was significantly associated with lymphatic and nodal invasion in studies conducted by Kaneko and his colleagues [35]. Therefore, cancerous HLA class I down regulation seems to be conducive to metastasis to other organs.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma

2014

View full text Add to dashboard Cite

BackgroundDefects in Human Leukocyte Antigen (HLA) class I antigen expression and/or function in tumor cells have been extensively investigated, because of their potential role in the escape of tumor cells from T cell recognition and destruction. The researchers evaluated HLA class I expression in tumor tissue as a prognostic factor in osteosarcoma patients and as a predictor of their survival. This retrospective cohort study was conducted at the pathology laboratory of Ain Shams University Hospital, and Ain Shams University Specialized Hospital during the period between January 2009 and January 2012.MethodsThe researchers investigated HLA class I expression in primary osteosarcoma by immunohistochemistry using EMR8-5 mAbs. Furthermore, researchers evaluated the correlation between HLA class I expression and the clinicopathological status and outcome in formalin fixed paraffin embedded tissues from thirty six (36) patients with osteosarcoma.ResultsA high expression of HLA class I was detected in 18 (50) % of tumor samples examined; while tumors with low or negative expression represented 9 (25%) cases each. Data indicate that the overall survival rate of patients with tumors highly expressing HLA class I was significantly higher than those with low or negative expression.ConclusionDown-regulation of class I antigen expression is associated with features of aggressive disease and a poorer prognosis. Therefore, it is imperative to identify HLA as a prognostic factor at the time of diagnosis to detect chemotherapy-resistant tumors and to generate a modified treatment regimen.Virtual slidesThe virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1159334857109547.

show abstract

“…In a cohort of 212 patients, downregulation of HLA class I expression was found in >30% of breast cancer samples and those patients with preserved HLA class I expression had better disease-free survival (Kaneko et al, 2011). Breast cancer cells can gain resistance to NK cell-mediated killing by expressing lower levels of the NK cell receptor ligand, MICB, whose expression is regulated by the metastasis-associated microRNA, miR-10b (Tsukerman et al, 2012).…”

Section: Tumor Cell-autonomous Modifications That Enable Breast Tumentioning

confidence: 99%

The immune system and inflammation in breast cancer

Jiang

Shapiro

2014

Molecular and Cellular Endocrinology

202

183

View full text Add to dashboard Cite

During different stages of tumor development the immune system can either identify and destroy tumors, or promote their growth. Therapies targeting the immune system have emerged as a promising treatment modality for breast cancer, and immunotherapeutic strategies are being examined in preclinical and clinical models. However, our understanding of the complex interplay between cells of the immune system and breast cancer cells is incomplete. In this article, we review recent findings showing how the immune system plays dual host-protective and tumor-promoting roles in breast cancer initiation and progression. We then discuss estrogen receptor α (ERα)-dependent and ERα-independent mechanisms that shield breast cancers from immunosurveillance and enable breast cancer cells to evade immune cell induced apoptosis and produce an immunosuppressive tumor microenvironment. Finally, we discuss protumorigenic inflammation that is induced during tumor progression and therapy, and how inflammation promotes more aggressive phenotypes in ERα positive breast cancers.

show abstract

Clinical implication of HLA class I expression in breast cancer

Cited by 109 publications

References 26 publications

Peptide intra-tumor injection for cancer immunotherapy

Peptide intra-tumor injection for cancer immunotherapy

Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma

The immune system and inflammation in breast cancer

Contact Info

Product

Resources

About